The largest database of trusted experimental protocols

3 morpholinosydnonimine

Manufactured by Merck Group
Sourced in United States

3-morpholinosydnonimine is a chemical compound used in laboratory settings. It serves as a tool for researchers and scientists to study various chemical and biological processes. The core function of this product is to provide a standardized reagent for specific applications, without making claims about its intended use or potential applications.

Automatically generated - may contain errors

2 protocols using 3 morpholinosydnonimine

1

Motor Neuron-Neuroblastoma Fusion Cell Line Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse NSC-34 hybrid cell line, a widely used motor neuron-neuroblastoma fusion line was chosen, as it expressed many of the morphological and physiological properties of motor neurons [26 (link)]. Cellswere grown in Dulbecco’s modified Eagle’s (DMEM)/F-12 medium supplemented with 10% fetal calf serum and 1% of a mixture of penicillin/streptomycin at 37°C in an atmosphere of 5% CO2 in air. Human neuroblastoma cells, SH-SY5Y cells were obtained from the ATCC (Rockville, USA), and were grown on tissue culture plates (Greiner, Hessle, UK) in DMEM, supplemented with 10% fetal calf serum, 1% L-glutamine and 1% SPN antibiotics (Biological Industries, Bet Haemek, Israel). Cells were incubated at 37°C in a humidified atmosphere with 5% CO2. Cells were exposed to peroxynitrite ion generator 3-morpholinosydnonimine (SIN-1, Sigma–Aldrich) or to glutamate (Sigma—Aldrich).
+ Open protocol
+ Expand
2

Ovariectomy and Estrogen Replacement in Myocardial Infarction

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female Wistar rats that were approximately 8 weeks of age and weighed 120–150 g were anaesthetized with Zoletil (20 mg/kg body weight, Virbac AH, Inc., France) and xylazine (9 mg/kg), and subsequently underwent ovariectomies (OVX) via bilateral dorsal incisions. Two weeks later, slow‐release 17β‐E2 pellets were implanted subcutaneously in the dorsal neck area (0.25 mg 60‐day release pellets, Innovative Research of America, Sarasota, Florida) 24 h after coronary ligation. These pellets ensured physiologic E2 plasma concentrations and prevented fluctuations in E2 level due to the oestrus cycle. Rats that did not undergo OVX and the other rats that did undergo OVX received placebo pellets. Oestrogen status was confirmed according to the weight of the uterus and plasma E2 level. To confirm the importance of the ROS signalling in E2‐induced macrophage skewing, we employed 3‐morpholinosydnonimine (2.5 mg/kg per day once daily, SIN‐1, a peroxynitrite generator; Sigma‐Aldrich, St. Louis, MO, USA). Thus, a total of five experimental groups were studied: sham group and infarction groups (non‐OVX intact, OVX, OVX/E2, and OVX/E2/SIN‐1, Figure 1). The heart was excised at Day 3 or 28 after MI as early and late stages of MI.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!